Chapter- 1: INTRODUCTION -- Complimentary
STUDY GOALS AND OBJECTIVES 1
REASONS FOR DOING THE STUDY 1
INTENDED AUDIENCE 1
SCOPE OF REPORT 2
METHODOLOGY AND INFORMATION SOURCES 2
ANALYST CREDENTIALS 3
RELATED BCC REPORTS 3
BCC ONLINE SERVICES 4
DISCLAIMER 4
Chapter-2: EXECUTIVE SUMMARY
EXECUTIVE SUMMARY 5
SUMMARY TABLE GLOBAL PRESCRIPTION AND OTC GASTROINTESTINAL DISORDER TREATMENT MARKET, THROUGH 2014 ($ MILLIONS) 6
SUMMARY FIGURE GLOBAL PRESCRIPTION AND OTC GASTROINTESTINAL DISORDER TREATMENT MARKET, 2007-2014 ($ MILLIONS) 6
Chapter-3: INDUSTRY OVERVIEW
STRUCTURE AND FUNCTION OF THE GASTROINTESTINAL SYSTEM 7
STRUCTURE AND FUNCTION (CONTINUED) 8
INGESTION AND PROPULSION OF FOOD 9
Mouth 9
Pharynx 9
Esophagus 10
DIGESTION AND ABSORPTION 10
Mouth 10
Stomach 10
Small Intestines 11
Physiology of Digestion 11
Physiology of Digestion (Continued) 12
ELIMINATION 13
Large Intestine 13
LIVER, BILIARY TRACT AND PANCREAS 14
LIVER 14
BILIARY TRACT 14
Bilirubin Metabolism 15
PANCREAS 15
GASTROINTESTINAL TRACT DISORDERS 15
DYSPHAGIA 15
Dysphagia (Continued) 16
ESOPHAGEAL AND ABDOMINAL PAIN 17
VOMITING 18
INTESTINAL GAS 18
CONSTIPATION 19
DIARRHEA 19
TABLE 1 CAUSES OF DIARRHEA 20
GASTROINTESTINAL TRACT WALL DISORDERS 21
GASTRITIS 21
TABLE 2 COMMON CAUSES OF GASTRITIS 21
GASTROENTERITIS 22
PEPTIC ULCER DISEASE 23
Peptic Ulcer Disease (Continued) 24
GASTRIC ULCERS 25
DUODENAL ULCERS 26
INFLAMMATORY BOWEL DISEASE 27
ULCERATIVE COLITIS 28
CROHN’S DISEASE 28
ENTEROCOLITIS 29
DIVERTICULAR DISEASE 30
GASTROINTESTINAL TRACT MOTILITY DISORDERS 30
IRRITABLE BOWEL SYNDROME 30
INTESTINAL OBSTRUCTION 31
GASTROINTESTINAL MALABSORPTION DISORDERS 32
CELIAC DISEASE 32
TROPICAL SPRUE 33
CANCERS OF THE GASTROINTESTINAL TRACT 33
ESOPHAGEAL CANCER 33
GASTRIC CANCER 34
LIVER CANCER 35
PANCREATIC CANCER 36
SMALL INTESTINAL CANCER 37
COLONIC POLYPS AND COLON CANCER 37
Colonic Polyps and (Continued) 38
U.S. DEMOGRAPHICS 39
TABLE 3 U.S. ESTIMATED INCIDENCE/PREVALENCE/MORTALITY OF SELECTED GASTROINTESTINAL CONDITIONS 39
TABLE 4 U.S. POPULATION BY SELECTED AGE GROUPS, 2009 AND 2014 (THOUSANDS) 40
FIGURE 1 U.S. POPULATION BY SELECTED AGE GROUPS, 2009 AND 2014 (THOUSANDS) 40
FIGURE 2 U.S. POPULATION SELECTED AGE GROUPS BY PERCENT OF TOTAL POPULATION, 2009 AND 2014 (%) 41
PILL-SIZED VIDEO CAMERA 42
PILLCAM ESO 42
SMARTPILL 42
RADIO FREQUENCY IDENTIFICATION TECHNOLOGY 43
IPHONE APPLICATION 43
ENTERIC NERVOUS SYSTEM 43
INSURANCE COVERAGE 44
MONOCLONAL ANTIBODIES 45
WYETH IN SUIT WITH STATES 46
GENERIC INFLUENCE 46
BRANDED VS OTC PROTON PUMP INHIBITORS 47
MAIL ORDER TRENDS 48
MAIL ORDER TRENDS (CONTINUED) 49
Chapter-4: PRESCRIPTION PRODUCT SEGMENTS BY TYPE
ANTIDIARRHEALS 50
SYSTEMICALLY ACTING ANTIDIARRHEALS 51
OPIUM PRODUCTS 51
TABLE 5 MARKETED ANTIDIARRHEAL PRODUCTS 52
MARKET SIZE AND GROWTH 52
TABLE 6 GLOBAL PRESCRIPTION ANTIDIARRHEAL MARKET, BY REGION, THROUGH 2014 ($ MILLIONS) 53
FIGURE 3 GLOBAL PRESCRIPTION ANTIDIARRHEAL MARKET, BY REGION, THROUGH 2014 ($ MILLIONS) 53
COMPETITIVE STRUCTURE AND MARKET SHARE 54
TABLE 7 GLOBAL PRESCRIPTION ANTIDIARRHEAL REVENUES AND MARKET SHARE LEVELS, BY MANUFACTURER, 2009 ($ MILLIONS/%) 54
FIGURE 4 GLOBAL PRESCRIPTION ANTIDIARRHEAL REVENUES, 2009 ($ MILLIONS) 55
ANTIEMETICS 55
LOCALLY ACTING ANTIEMETICS 55
CENTRALLY ACTING ANTIEMETICS 56
ANTIDOPAMINERGICS 56
Antidopaminergics (Continued) 57
ANTICHOLINERGICS 58
MISCELLANEOUS ANTIEMETICS 58
Miscellaneous Antiemetics (Continued) 59
Miscellaneous Antiemetics (Continued) 59
TABLE 8 MARKETED ANTIEMETIC PRODUCTS 60
TABLE 8 (CONTINUED) 61
MARKET SIZE AND GROWTH 61
TABLE 9 GLOBAL PRESCRIPTION ANTIEMETIC MARKET BY REGION, THROUGH 2014 ($ MILLIONS) 61
FIGURE 5 GLOBAL PRESCRIPTION ANTIEMETIC MARKET BY REGION, 2007-2014 ($ MILLIONS) 62
COMPETITIVE STRUCTURE AND MARKET SHARE 62
TABLE 10 GLOBAL PRESCRIPTION ANTIEMETIC REVENUES AND MARKET SHARE BY MANUFACTURER, 2009 ($ MILLIONS/%) 63
FIGURE 6 GLOBAL PRESCRIPTION ANTIEMETICS REVENUES BY MANUFACTURER, 2009 ($ MILLIONS) 63
GASTROINTESTINAL CANCER TREATMENTS 63
GASTROINTESTINAL CANCER (CONTINUED) 64
GASTROINTESTINAL CANCER (CONTINUED) 65
TABLE 11 MARKETED GASTROINTESTINAL CANCER PRODUCTS 66
MARKET SIZE AND GROWTH 66
TABLE 12 GLOBAL PRESCRIPTION GASTROINTESTINAL CANCER DRUG MARKET BY REGION, THROUGH 2014 ($ MILLIONS) 66
FIGURE 7 GLOBAL PRESCRIPTION GASTROINTESTINAL CANCER DRUG MARKET BY REGION, 2007-2014 ($ MILLIONS) 67
COMPETITIVE STRUCTURE AND MARKET SHARE 67
TABLE 13 GLOBAL PRESCRIPTION GASTROINTESTINAL CANCER DRUG REVENUES AND MARKET SHARE, 2009 ($ MILLIONS/%) 68
FIGURE 8 GLOBAL PRESCRIPTION GASTROINTESTINAL CANCER DRUG REVENUES, 2009 ($ MILLIONS) 68
H2 INHIBITORS 68
H2 INHIBITORS (CONTINUED) 69
H2 INHIBITORS (CONTINUED) 70
H2 INHIBITORS (CONTINUED) 71
TABLE 14 MARKETED H2 INHIBITORS PRODUCTS 72
MARKET SIZE AND GROWTH 72
TABLE 15 GLOBAL PRESCRIPTION H2 INHIBITOR MARKET BY REGION, THROUGH 2014 ($ MILLIONS) 73
FIGURE 9 GLOBAL PRESCRIPTION H2 INHIBITOR MARKET BY REGION, 2007-2014 ($ MILLIONS) 73
COMPETITIVE STRUCTURE AND MARKET SHARE 73
TABLE 16 GLOBAL PRESCRIPTION H2 INHIBITOR REVENUES AND MARKET SHARE, 2009 ($ MILLIONS/%) 74
FIGURE 10 GLOBAL PRESCRIPTION H2 INHIBITOR REVENUES, 2009 ($ MILLIONS) 74
LAXATIVES 74
LAXATIVES (CONTINUED) 75
TABLE 17 MARKETED LAXATIVE PRODUCTS 76
MARKET SIZE AND GROWTH 77
TABLE 18 GLOBAL PRESCRIPTION LAXATIVE MARKET BY REGION, THROUGH 2014 ($ MILLIONS) 77
FIGURE 11 GLOBAL PRESCRIPTION LAXATIVE MARKET BY REGION, 2007-2014 ($ MILLIONS) 78
COMPETITIVE STRUCTURE AND MARKET SHARE 78
TABLE 19 GLOBAL PRESCRIPTION LAXATIVE REVENUES AND MARKET SHARE, 2009 ($ MILLIONS/%) 78
FIGURE 12 GLOBAL PRESCRIPTION LAXATIVE REVENUES, 2009 ($ MILLIONS) 79
PROTON PUMP INHIBITORS 79
PROTON PUMP INHIBITORS (CONTINUED) 80
PROTON PUMP INHIBITORS (CONTINUED) 81
TABLE 20 MARKETED PROTON PUMP INHIBITOR PRODUCTS 82
MARKET SIZE AND GROWTH 82
TABLE 21 GLOBAL PRESCRIPTION PROTON PUMP INHIBITOR MARKET BY REGION, THROUGH 2014 ($ MILLIONS) 82
FIGURE 13 GLOBAL PRESCRIPTION PROTON PUMP INHIBITOR MARKET BY REGION, 2007-2014 ($ MILLIONS) 83
COMPETITIVE STRUCTURE AND MARKET SHARE 83
TABLE 22 GLOBAL PRESCRIPTION PROTON PUMP INHIBITOR REVENUES AND MARKET SHARE BY MANUFACTURER, 2009 ($ MILLIONS/%) 84
FIGURE 14 GLOBAL PRESCRIPTION PROTON PUMP INHIBITOR REVENUES BY MANUFACTURER, 2009 ($ MILLIONS) 84
BOWEL ANTI-INFLAMMATORY 84
BOWEL ANTI-INFLAMMATORY (CONTINUED) 85
BOWEL ANTI-INFLAMMATORY (CONTINUED) 86
TABLE 23 MARKETED BOWEL ANTI-INFLAMMATORY PRODUCTS 87
MARKET SIZE AND GROWTH 87
TABLE 24 GLOBAL PRESCRIPTION BOWEL INFLAMMATORY AGENT MARKET BY REGION, THROUGH 2014 ($ MILLIONS) 87
FIGURE 15 GLOBAL PRESCRIPTION BOWEL INFLAMMATORY AGENT MARKET BY REGION, 2007-2014 ($ MILLIONS) 88
COMPETITIVE STRUCTURE AND MARKET SHARE 88
TABLE 25 GLOBAL PRESCRIPTION BOWEL INFLAMMATORY AGENT REVENUES AND MARKET SHARE, 2009 ($ MILLIONS/%) 89
FIGURE 16 GLOBAL PRESCRIPTION BOWEL INFLAMMATORY AGENT REVENUES BY MANUFACTURER, 2009 ($ MILLIONS) 89
OTHER GASTROINTESTINAL PRODUCTS 89
ANTISPASMODICS 90
TABLE 26 MARKETED ANTISPASMODIC PRODUCTS 90
DIGESTANTS 90
GASTRIC ACIDIFIERS 91
PANCREATIC ENZYMES 91
TABLE 27 MARKETED DIGESTANT PRODUCTS 92
EVACUANTS 92
TABLE 28 MARKETED EVACUANTS PRODUCTS 92
MUCOSAL PROTECTANTS 93
TABLE 29 MARKETED MUCOSAL PROTECTANT PRODUCTS 93
PROSTAGLANDINS 93
TABLE 30 MARKETED PROSTAGLANDIN PRODUCTS 94
STIMULANTS 94
TABLE 31 MARKETED STIMULANT PRODUCTS 94
MARKET SIZE AND GROWTH 95
TABLE 32 GLOBAL PRESCRIPTION OTHER GASTROINTESTINAL DRUG MARKET BY REGION, THROUGH 2014 ($ MILLIONS) 95
FIGURE 17 GLOBAL PRESCRIPTION OTHER GASTROINTESTINAL DRUG MARKET BY REGION, 2007-2014 ($ MILLIONS) 95
COMPETITIVE STRUCTURE 96
TOTAL GLOBAL PRESCRIPTION GASTROINTESTINAL MARKET SIZE AND GROWTH 96
TABLE 33 GLOBAL PRESCRIPTION GASTROINTESTINAL DISORDER TREATMENT REVENUES BY CATEGORY, THROUGH 2014 ($ MILLIONS) 96
FIGURE 18 GLOBAL PRESCRIPTION GASTROINTESTINAL DISORDER TREATMENT REVENUES BY CATEGORY, 2007-2014 ($ MILLIONS) 97
TOTAL U.S. PRESCRIPTION GASTROINTESTINAL COMPETITIVE ANALYSIS 97
TABLE 34 MANUFACTURERS MARKET SHARE OF PRESCRIPTION GASTROINTESTINAL DISORDER TREATMENT REVENUES, (ESTIMATED 2009) 98
FIGURE 19 MANUFACTURERS MARKET SHARE OF PRESCRIPTION GASTROINTESTINAL DISORDER TREATMENT REVENUES, 2009 ESTIMATED (%) 99
Chapter-5: OTC PRODUCT SEGMENTS BY TYPE
ANTACIDS 100
SYSTEMIC ANTACIDS 101
Sodium Bicarbonate 101
NONSYSTEMIC ANTACIDS 101
Calcium Carbonate 101
Aluminum Products 102
Magnesium Products 102
Combination Products 103
TABLE 35 MARKETED OTC ANTACID PRODUCTS 103
TABLE 35 (CONTINUED) 104
MARKET SIZE AND GROWTH 104
TABLE 36 GLOBAL OTC ANTACID MARKET BY REGION, THROUGH 2014 ($ MILLIONS) 104
FIGURE 20 GLOBAL OTC ANTACID MARKET BY REGION, 2007-2014 ($ MILLIONS) 105
COMPETITIVE STRUCTURE AND MARKET SHARE 105
TABLE 37 GLOBAL OTC ANTACID REVENUES AND MARKET SHARE BY MANUFACTURER, 2009 ($ MILLIONS/%) 106
FIGURE 21 GLOBAL OTC ANTACID MARKET SHARE BY MANUFACTURER, 2009 (%) 106
LOCALLY ACTING ANTIDIARRHEALS 106
ADSORBENTS 107
INTESTINAL FLORA MODIFIERS 108
TABLE 38 MARKETED OTC ANTIDIARRHEAL PRODUCTS 108
MARKET SIZE AND GROWTH 108
TABLE 39 GLOBAL OTC ANTIDIARRHEALS MARKET BY REGION, THROUGH 2014 ($ MILLIONS) 109
FIGURE 22 GLOBAL OTC ANTIDIARRHEALS MARKET BY REGION, 2007-2014 ($ MILLIONS) 109
COMPETITIVE STRUCTURE AND MARKET SHARE 110
TABLE 40 GLOBAL OTC ANTIDIARRHEALS REVENUES BY MANUFACTURER, 2009 ($ MILLIONS/%) 110
FIGURE 23 GLOBAL OTC ANTIDIARRHEALS MARKET SHARE BY MANUFACTURER, 2009 (%) 110
H2 INHIBITORS 111
H2 INHIBITORS (CONTINUED) 112
H2 INHIBITORS (CONTINUED) 113
TABLE 41 MARKETED OTC H2 INHIBITORS PRODUCTS 114
MARKET SIZE AND GROWTH 114
TABLE 42 GLOBAL OTC H2 INHIBITOR MARKET BY REGION, THROUGH 2014 ($ MILLIONS) 114
FIGURE 24 GLOBAL OTC H2 INHIBITOR MARKET BY REGION, 2007-2014 ($ MILLIONS) 115
COMPETITIVE STRUCTURE AND MARKET SHARE 115
TABLE 43 GLOBAL OTC H2 INHIBITOR REVENUES AND MARKET SHARE BY MANUFACTURER, 2009 ($ MILLIONS/%) 116
FIGURE 25 GLOBAL OTC H2 INHIBITOR MARKET SHARE BY MANUFACTURER, 2009 (%) 116
PROTON PUMP INHIBITORS 116
OMEPRAZOLE (PRILOSEC, PROCTER & GAMBLE) 116
TABLE 44 MARKETED OTC PROTON PUMP INHIBITOR PRODUCTS 117
MARKET SIZE AND GROWTH 117
TABLE 45 GLOBAL OTC PROTON PUMP INHIBITOR MARKET BY REGION, THROUGH 2014 ($ MILLIONS) 118
FIGURE 26 GLOBAL OTC PROTON PUMP INHIBITOR MARKET BY REGION, 2007-2014 ($ MILLIONS) 118
COMPETITIVE STRUCTURE AND MARKET SHARE 119
TABLE 46 GLOBAL OTC PROTON PUMP INHIBITOR REVENUES AND MARKET SHARE BY MANUFACTURER, 2009 ($ MILLIONS/%) 119
FIGURE 27 GLOBAL OTC PROTON PUMP INHIBITOR MARKET SHARE BY MANUFACTURER, 2009 (%) 119
LAXATIVES 120
TABLE 47 MARKETED OTC LAXATIVE PRODUCTS 120
TABLE 47 (CONTINUED) 121
MARKET SIZE AND GROWTH 121
TABLE 48 GLOBAL OTC LAXATIVES MARKET BY REGION, THROUGH 2014 ($ MILLIONS) 121
FIGURE 28 GLOBAL OTC LAXATIVE MARKET BY REGION, 2007-2014 ($ MILLIONS) 122
COMPETITIVE STRUCTURE AND MARKET SHARE 122
TABLE 49 GLOBAL OTC LAXATIVE REVENUES AND MARKET SHARE BY MANUFACTURER, 2009 ($ MILLIONS/%) 122
FIGURE 29 GLOBAL OTC LAXATIVE MARKET SHARE BY MANUFACTURER, 2009 (%) 123
TOTAL OTC GASTROINTESTINAL DRUG MARKET SIZE AND GROWTH 123
TABLE 50 GLOBAL OTC GASTROINTESTINAL DISORDER TREATMENT MARKET BY PRODUCT CATEGORY, THROUGH 2014 ($ MILLIONS) 123
FIGURE 30 GLOBAL OTC GASTROINTESTINAL DISORDER TREATMENT MARKET BY PRODUCT CATEGORY, 2007-2014 ($ MILLIONS) 124
TOTAL OTC GASTROINTESTINAL DRUG COMPETITIVE ANALYSIS 124
TABLE 51 TOTAL MANUFACTURERS’ REVENUES AND MARKET SHARE OF OTC GASTROINTESTINAL DISORDER TREATMENTS, ESTIMATED 2009 ($ MILLIONS/%) 125
FIGURE 31 TOTAL MANUFACTURERS’ MARKET SHARE OF OTC GASTROINTESTINAL DISORDER TREATMENTS, ESTIMATED 2009 (%) 125
RESEARCH AND DEVELOPMENT 125
METOSOLV ODT 126
NEXIUM LOW-DOSE ASPIRIN COMBINATION 126
REZONIC 126
SANVAR 126
TAK-390MR (KAPIDEX) 126
ZENPEP 127
AB-1001 127
ALICAFORSEN 127
APF 530 128
CROFELEMER 128
HUMIRA 128
LINACLOTIDE 128
METHYLNALTREXONE (MNTX) (RELSTAR) 128
MLN 0002 (VEDOLIZUMAB) 129
ORBEC 129
PROCHYMAL 129
RENZAPRIDE 129
REMICADE 130
REZULAR 130
RIFAXIMAN (XIFAXAN) 130
SUTENT 130
ALICAFORSEN ENEMA 130
DEXTOFISOPAM 131
EKB-569 131
GTI-2040 131
PUMOSETRAG 131
RDP-58 132
SORAPRAZAN 132
TALNETANT 132
BL-1030 132
BL-1050 132
TABLE 52 GASTROINTESTINAL DISORDER TREATMENTS IN DEVELOPMENT 133
TABLE 52 (CONTINUED) 134
TABLE 52 (CONTINUED) 135
TABLE 52 (CONTINUED) 136
TABLE 52 (CONTINUED) 137
TABLE 52 (CONTINUED) 138
TABLE 52 (CONTINUED) 139
TOTAL MARKET ANALYSIS 139
TABLE 53 GLOBAL PRESCRIPTION AND OTC GASTROINTESTINAL DISORDER MARKET BY CATEGORY, THROUGH 2014 ($ MILLIONS) 139
FIGURE 32 GLOBAL PRESCRIPTION AND OTC GASTROINTESTINAL DISORDER TREATMENT MARKET BY CATEGORY, 2007-2014 ($ MILLIONS) 140
Chapter-6: INDUSTRY PARTICIPANTS BY PRODUCT TYPE
TABLE 54 GASTROINTESTINAL DISORDER TREATMENT MANUFACTURERS’ REVENUES AND MARKET SHARE BY TYPE, 2009 ($ MILLIONS/%) 141
FIGURE 33 GASTROINTESTINAL DISORDER TREATMENT MANUFACTURERS’ MARKET SHARE BY TYPE, 2009 (%) 142
COMPANY PROFILES 142
ASTRAZENECA 142
History 143
AXCAN PHARMA, INC. 143
History 144
CENTOCOR, INC. 145
History 146
EISAI, INC. 146
History 147
GENENTECH, INC. 147
History 148
GLAXOSMITHKLINE 148
Glaxosmithkline (Continued) 149
Glaxosmithkline (Continued) 150
History 151
JOHNSON & JOHNSON 151
History 151
MCNEIL CONSUMER HEALTHCARE 152
History 152
MERCK & CO., INC. 152
History 153
NOVARTIS INTERNATIONAL AG 153
History 154
PFIZER, INC. 154
History 155
PROCTER & GAMBLE CO. 155
History 156
ROCHE 156
History 157
SANOFI-AVENTIS 157
History 157
SALIX PHARMACEUTICALS, LTD. 158
History 158
SOLVAY PHARMACEUTICALS 159
History 159
TAKEDA PHARMACEUTICALS NORTH AMERICA 160
History 160
WYETH 161
History 162
Chapter-7: CONTACT INFORMATION FOR GASTROINTESTINAL MARKET PARTICIPANTS
3M CORP. 163
ABBOTT LABORATORIES 163
ABEILLE PHARMA, INC. 163
ACAMBIS, PLC 163
ACE BIOSCIENCES A/S 163
AGI THERAPEUTICS, INC. 163
ALCHEMIA, LTD. 164
ALIZYME, PLC 164
ALLERGAN, INC. 164
ALLSCRIPTS HEALTHCARE SOLUTIONS, INC. 164
ALTANA PHARMA AG 164
ALVINE PHARMACEUTICALS, INC. 164
AMARIN CORP. 164
AMGEN, INC. 165
ANTIGENICS, INC. 165
APOTHECON B.V. 165
AP PHARMA, INC. 165
ARCO PHARMACEUTICALS 165
ASPHELIA PHARMACEUTICALS, INC. 165
ARYX THERAPEUTICS, INC 165
ASTELLAS PHARMA, INC. 166
ASTRAZENECA, PLC 166
AXCAN PHARMA, INC. 166
BERTEK (MYLAN LABORATORIES INC.) 166
BIOBALANCE, INC. 166
BIOGEN IDEC, INC. 166
BIOLINERX, LTD. 167
BRAINTREE LABORATORIES, INC. 167
BRISTOL-MYERS SQUIBB CO. 167
CELLDEX THERAPEUTICS, INC. 167
CENTOCOR ORTHO BIOTECH, INC. 167
CEPHALON, INC. 167
CERIMON PHARMA, INC. 167
CHEMOCENTRYX, INC. 168
CLAVIS PHARMA ASA 168
COSMO PHARMACEUTICALS SPA 168
CYTOKINE PHARMASCIENCES, INC. 168
DEBIOPHARM S.A. 168
DOR BIOPHARMA, INC. 168
EISAI CO., LTD. 169
ELAN CORPORATION, PLC 169
EMD SERONO, INC. 169
ENZO 169
EURAND PHARMACEUTICALS, INC. 169
EVOKE PHARMA 169
FRESENIUS KABI AG 169
GENENTECH, INC. 170
GENZYME GENERAL 170
GLAXOSMITHKLINE, PLC 170
GLAXOSMITHKLINE CONSUMER HEALTHCARE 170
GLENMARK PHARMACEUTICALS, LTD. 170
H3 PHARMA, INC. 170
HELSINN HEALTHCARE 171
HOFFMAN-LAROCHE, LTD. (ROCHE) 171
HYPERION THERAPEUTICS, INC. 171
IMMUCELL CORP. 171
ISIS PHARMACEUTICALS. INC. 171
JANSSEN PHARMACEUTICA PRODUCTS, LP (JOHNSON & JOHNSON) 171
JOHNSON & JOHNSON 171
LORUS THERAPEUTICS, INC. 172
MCNEIL CONSUMER & SPECIALTY PHARMACEUTICALS 172
MEDISCA, INC. 172
MERCK & CO., INC. 172
MONARCH LABS 172
NABI BIOPHARMACEUTICALS 172
NOVARTIS CORP. 172
NPS PHARMACEUTICALS, INC. 173
OTSUKA AMERICA PHARMACEUTICAL, INC. 173
PFIZER, INC. 173
THE PROCTER & GAMBLE CO. 173
PRODIGENE, INC. 173
PROGENICS PHARMACEUTICALS, INC. 173
RAVEN BIOTECHNOLOGIES, INC. 173
RELIANT PHARMACEUTICALS, INC. 174
ROXANE LABORATORIES, INC. 174
SALIX PHARMACEUTICALS, LTD. 174
SANOFI-AVENTIS 174
SANTARUS, INC. 174
SCHERING AG 174
SCHWARZ PHARMA AG 174
SERONO S.A. 175
SHIRE PHARMACEUTICALS GROUP, PLC 175
SOLVAY S.A. 175
SUCAMPO PHARMACEUTICALS, INC. 175
SWISS AGENCY FOR THERAPEUTIC PRODUCTS (SWISSMEDIC) 175
TAKEDA PHARMACEUTICAL NORTH AMERICA 175
TARGACEPT, INC. 176
THERAVANCE, INC. 176
UCB PHARMA, INC. 176
UNIMED PHARMACEUTICALS, INC. 176
PHARMOS PHARMACEUTICALS, INC. 176
WATSON PHARMACEUTICALS, INC. 176
WYETH (WHITEHALL-ROBINS HEALTHCARE, INC.) 176
